Development and Commercialization Event Payments Clause Samples
Development and Commercialization Event Payments. Roche shall provide Emisphere with written notice of the first occurrence of each of the events set forth below with respect to each Product within ten (10) days after such occurrence. Within *** calendar days following the later of (i) receipt of an invoice from Emisphere, and (ii) the first occurrence of each of the events set forth below with respect to each Product, Roche shall pay to Emisphere the applicable payment set forth below, whether such milestone is achieved by Roche, its Affiliate or any of their respective sublicensees: *** *** *** *** *** *** *** *** *** *** * Or first pivotal clinical trial designed for filing of an NDA. In the event that, at the time the first NDA is filed with respect to a Product, one or both of these payments have not been paid for such Product, then Roche shall pay such payment(s) concurrently with the payment for filing of the first NDA with respect to such Product. The payments set forth above in this Section 6.2 shall be payable on a Product-by-Product basis, and each of such payments shall be payable only once for each Product, regardless of the number of indications for which such Product is developed or approved or the number of times each event occurs for a particular Product. All payments made to Emisphere pursuant to this Section 6.4 are non-refundable and may not be credited against any other payments payable by Roche to Emisphere under this Agreement.
Development and Commercialization Event Payments. Roche shall pay SQZ in relation to the achievements of development and commercialization milestone events with respect to Licensed Products. The development and commercialization milestone payments under this Section 12.7 shall be paid as follows: On a Licensed Antigen Product-by-Licensed Antigen Product basis, Roche shall pay SQZ the following milestone event payments for the first achievement of each of the corresponding milestone events by each such Licensed Antigen Product: [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] Roche shall pay SQZ the following one-time milestone event payments for the first achievement of each of the corresponding milestone events by the first Licensed TCL Product to achieve such event: [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [********] [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. [********] [********] [********] [********] [********] [********] [********] [********] [********] * NOA filing in the EU means either (a) the filing of an NOA in a country of the EU or (b) a filing of an NOA through a centralized procedure in the EU. Regulatory Approval in the EU means either (a)receipt of Regulatory Approval from a country of the EU or (b) receipt of Regulatory Approval from the EMA through a centralized procedure. Upon reaching development or commercialization events, Roche shall timely notify SQZ and the applicable development or commercialization event payments shall be paid by Roche to SQZ within [********] from occurrence of the applicable event and receipt of an invoice from SQZ.
Development and Commercialization Event Payments